MediWound (MDWD) Competitors

MediWound (NASDAQ:MDWD) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, community ranking, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

Do analysts recommend MDWD or AVBP?

MediWound currently has a consensus price target of $31.33, suggesting a potential upside of 88.08%. ArriVent BioPharma has a consensus price target of $39.00, suggesting a potential upside of 105.37%. Given ArriVent BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe ArriVent BioPharma is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
ArriVent BioPharma	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17

Is MDWD or AVBP more profitable?

ArriVent BioPharma has a net margin of 0.00% compared to MediWound's net margin of -142.29%. ArriVent BioPharma's return on equity of -43.89% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-142.29%	-82.17%	-33.67%
ArriVent BioPharma	N/A	-43.89%	-29.67%

Does the MarketBeat Community favor MDWD or AVBP?

MediWound received 376 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 62.23% of users gave MediWound an outperform vote.

Company	Underperform	Outperform
MediWound	Outperform Votes 397 62.23%	Underperform Votes 241 37.77%
ArriVent BioPharma	Outperform Votes 21 100.00%	Underperform Votes No Votes

Which has higher valuation & earnings, MDWD or AVBP?

MediWound has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$20.22M	8.89	-$6.72M	-$3.07	-5.43
ArriVent BioPharma	N/A	N/A	-$69.33M	-$2.57	-7.39

Do institutionals & insiders have more ownership in MDWD or AVBP?

46.8% of MediWound shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 9.2% of MediWound shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has more volatility and risk, MDWD or AVBP?

MediWound has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, ArriVent BioPharma has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.

Does the media favor MDWD or AVBP?

In the previous week, MediWound had 7 more articles in the media than ArriVent BioPharma. MarketBeat recorded 25 mentions for MediWound and 18 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.77 beat MediWound's score of 0.34 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediWound	2 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
ArriVent BioPharma	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ArriVent BioPharma beats MediWound on 11 of the 18 factors compared between the two stocks.